“A scientific career is really worth it,” says Hong Liu, Ph.D., an assistant professor of biochemistry and molecular biology at Tulane University School of Medicine in New Orleans, Louisiana. Check out the highlights of our interview with Dr. Liu below to learn about his journey as a scientist and his advice for students.
Q: What makes a career in science exciting?
A: I think there are at least two things that make a science career very exciting. The first is that doing science means you have freedom to explore a lot of new ideas. The second thing is it’s rewarding. The “rewarding” I’m talking about here is not like how much money you can make. It’s rewarding in the answers you find and the new knowledge you reveal.
Students, teachers, and other curious minds can step into a scientific imaging lab with a free online interactive developed by NIGMS and Scholastic. Imaging tools help scientists unlock the mysteries of our cells and molecules. A better understanding of this tiny world can help researchers learn about the body’s normal and abnormal processes and lead to more effective, targeted treatments for illnesses.
Josephine (Josie) Chandler, Ph.D., first became interested in science when she took a high school chemistry class. In college, she fell in love with microbiology and ultimately earned a Ph.D. in the field. Today, she’s an associate professor of molecular biosciences at the University of Kansas in Lawrence, where her lab investigates interactions in bacterial communities. By better understanding these interactions, scientists may find new ways to stop infections or break down environmental pollutants—a process known as bioremediation.
“If you bring a public health program to people where they live, you can get amazing results,” says Peter Katzmarzyk, Ph.D., a professor of pediatric obesity and diabetes at Pennington Biomedical Research Center, Louisiana State University. Specifically, bringing health programs into underserved communities can lead to strong engagement and positive changes in people’s health. Dr. Katzmarzyk is part of the NIGMS-funded Louisiana Clinical & Translational Science Center (LA CaTS), a collaboration between 10 academic, research, and health care delivery institutions that focuses on reducing health disparities in Louisiana.
As computers have advanced over the past few decades, researchers have been able to work with larger and more complex datasets than ever before. The science of using computers to investigate biological data is called bioinformatics, and it’s helping scientists make important discoveries, such as finding versions of genes that affect a person’s risk for developing various types of cancer. Many scientists believe that almost all biologists will use bioinformatics to some degree in the future.
However, bioinformatics isn’t always included in college biology programs, and many of today’s researchers received their training before bioinformatics was widely taught. To address these gaps, the bioinformatics cores of the five Northeast IDeA Networks of Biomedical Research Excellence (INBREs)—located in Maine, Rhode Island, Delaware, Vermont, and New Hampshire—have worked together to offer basic bioinformatics training to students and researchers. The collaboration started in 2009 with a project where researchers sequenced the genome of a fish called the little skate (Leucoraja erinacea) and used the data to develop trainings.
“What we’re trying to do is support the students’ attachment to being a scientist, to becoming part of the community,” says Douglas McMahon, Ph.D., the Stevenson Professor of Biological Sciences at Vanderbilt University in Nashville, Tennessee, and a co-director of Vanderbilt’s Maximizing Access to Research Careers (MARC) program. MARC focuses on undergraduates from diverse backgrounds who are in the biomedical sciences and plan to pursue a Ph.D. or M.D./Ph.D. degree after graduation.
For years, NIGMS has funded MARC programs throughout the United States and its territories; Vanderbilt joined their ranks in 2020. In June of that year, Dr. McMahon and Katherine Friedman, Ph.D., an associate professor of biological sciences at Vanderbilt and co-director of its MARC program, welcomed the initial cohort of six rising juniors. “MARC is a great opportunity because it focuses on helping people reach their Ph.D. goals who don’t really have others around them who know how to get there,” says Sim Plotkin, a molecular and cellular biology major. “For me, that’s really helpful because I’ll be the first in my family to graduate from college.”
NIGMS’ Small Business Technology Transfer (STTR) program works toward more effective methods for patient screening, diagnosis, and treatment.
Translating lab discoveries into health care products requires large investments of time and resources. Through the STTR Regional Technology Transfer Accelerator Hubs for IDeA States program, NIGMS helps researchers interested in transitioning their discoveries and/or inventions into products. Here are the stories of three researchers working with the XLerator Hub, which funds projects in the southeastern United States and Puerto Rico.
Ending Diagnostic Delays for Endometriosis
Dr. Idhaliz Flores-Caldera. Credit: Courtesy of Dr. Flores-Caldera.
Idhaliz Flores-Caldera, Ph.D., a professor of basic sciences and OB-GYN at Ponce Health Sciences University in Puerto Rico, has studied endometriosis for nearly 20 years. Endometriosis occurs when endometrial tissue, which typically lines the uterus, grows elsewhere in the body. Dr. Flores-Caldera first had the idea for a noninvasive diagnostic test for the disorder about 10 years ago. But it was only when she learned about funding opportunities from the XLerator Hub that she saw a path to validating her preliminary research findings and eventually commercializing her test.
Dr. Flores-Caldera applied for and was accepted into the hub’s proof-of-concept program, Ideas to Products, which funds researchers to flesh out ideas they want to commercialize. “I am very appreciative of how the program has provided me with tools and knowledge about commercializing a product and the process of patenting a product,” she says. “In general, scientists aren’t educated on this important topic.”
NIGMS and Scholastic bring you our latest issue of Pathways, which focuses on imaging tools that help scientists unlock the mysteries of our cells and molecules. A better understanding of this tiny world can help researchers learn about the body’s normal and abnormal processes and lead to more effective, targeted treatments for illnesses.
Pathways is designed for students in grades 6 through 12. This collection of free resources teaches students about basic science and its importance to health, as well as exciting research careers.
ACTIV clinical trials will evaluate the safety and efficacy of COVID-19 treatments and vaccines. Credit: iStock.
Since the virus that causes COVID-19, known as SARS-CoV-2, was first reported in late 2019, scientists have launched hundreds of studies on strategies for diagnosis, prevention, and treatment. To prioritize the most promising vaccine and therapeutics candidates, streamline clinical trials, and coordinate regulatory processes, the National Institutes of Health (NIH) and the Foundation for the NIH have established the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership. ACTIV brings together eight government entities, 20 biopharmaceutical companies, and four nonprofit organizations.
Spike proteins on the surface of a coronavirus. Credit: David Veesler, University of Washington.
Since the start of the COVID-19 pandemic, researchers from many areas of biomedical science have worked together to learn how this new disease affects the human body, how to prevent its spread, and how to treat it. Severe cases of COVID-19 and cases of sepsis share many symptoms. Sepsis is the body’s overactive and extreme response to an infection. It’s unpredictable and can progress rapidly. Without prompt treatment, it can lead to tissue damage, organ failure, and death.
Sepsis has similarities with some cases of COVID-19, most likely because the two conditions trigger the same reactions at the cellular level. Researchers have studied these reactions in sepsis for many years.
“When we look back on 2020 and the speed with which progress was made against COVID-19, two features will stand out,” says John Younger, M.D., a member of the NIGMS Advisory Council who recently co-chaired a working group on advancing sepsis research. “The first is how quickly the biotechnology community came together to develop vaccine candidates. The second, and arguably the most immediately impactful, is how caregivers and clinical researchers were able to rapidly refine the care of COVID-19 patients based on decades of experience with sepsis.”
This post highlights a few of the many sepsis researchers supported by NIGMS who are applying their expertise to COVID-19.